Health Professional Radio - Podcast

Chris Bradley, CEO of Loki Therapeutics discusses Loki's proprietary AWAKE™ strategy that completely bypasses the major challenges faced by traditional immunotherapy approaches. AWAKE reactivates and redirects pre-existing, life-long Memory T-cells created during childhood vaccination to target and eliminate cancer cells rather than training naïve T-cells against tumor antigens like traditional immunotherapy.